NASDAQ:SPRB Spruce Biosciences (SPRB) Stock Price, News & Analysis $46.20 -0.47 (-1.01%) Closing price 04:00 PM EasternExtended Trading$46.33 +0.13 (+0.28%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Spruce Biosciences Stock (NASDAQ:SPRB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Spruce Biosciences alerts:Sign Up Key Stats Today's Range$45.44▼$47.4050-Day Range$38.98▼$59.6752-Week Range$38.06▼$127.90Volume50,234 shsAverage Volume78,454 shsMarket Capitalization$132.59 millionP/E RatioN/ADividend YieldN/APrice Target$158.33Consensus RatingModerate Buy Company Overview Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for rare endocrine disorders. The company’s research is centered on conditions in which abnormal hormone production or regulation creates significant health risks and limited treatment options. Its lead investigational product is tildacerfont, an oral, selective corticotropin-releasing factor type 1 receptor antagonist. Spruce has studied tildacerfont as a potential treatment for congenital adrenal hyperplasia, a rare genetic disorder affecting the adrenal glands, and has evaluated its ability to reduce hormone imbalances associated with the disease. Tildacerfont is investigational and has not been approved for commercial use. Spruce Biosciences was founded in 2014 and is headquartered in San Francisco, California. The company’s development activities have included clinical research conducted in the United States and other regions. As a development-stage biotechnology company, Spruce has focused primarily on advancing its endocrine-disease pipeline rather than marketing an established portfolio of commercial products.AI Generated. May Contain Errors. Read More Spruce Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreSPRB MarketRank™: 2.420852956565 of 5 starsSpruce Biosciences scored higher than 48% of companies evaluated by MarketBeat, and ranked 571st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingSpruce Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 11 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSpruce Biosciences has a consensus price target of $158.33, representing about 242.7% upside from its current price of $46.20.Amount of Analyst CoverageSpruce Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Spruce Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Spruce Biosciences are expected to grow in the coming year, from ($25.53) to ($1.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spruce Biosciences is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spruce Biosciences is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpruce Biosciences has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.32% of the float of Spruce Biosciences has been sold short.Short Interest Ratio / Days to CoverSpruce Biosciences has a short interest ratio ("days to cover") of 6.95.Change versus previous monthShort interest in Spruce Biosciences has recently increased by 1.77%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSpruce Biosciences does not currently pay a dividend.Dividend GrowthSpruce Biosciences does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.26 News SentimentSpruce Biosciences has a news sentiment score of -0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Spruce Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for SPRB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Spruce Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders4.30% of the stock of Spruce Biosciences is held by insiders.Percentage Held by Institutions91.71% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Spruce Biosciences' insider trading history. Receive SPRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPRB Stock News HeadlinesSpruce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10 at 11:00 PM | marketscreener.comMSpruce Biosciences Faces Funding Risk as Uncertainty Looms Over TA-ERT FDA Priority Review Voucher and Sale ProspectsNovember 10 at 1:11 AM | tipranks.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 11 at 1:00 AM | Base Camp Trading (Ad)Spruce Biosciences Separates CAH Program Into New Company Adrenyx BiosciencesNovember 9 at 3:04 PM | rttnews.comSpruce Biosciences establishes Adrenyx subsidiary to develop CAH treatment CRHX-101November 9 at 3:04 PM | msn.comComparing Spruce Biosciences (SPRB) and Its RivalsNovember 5, 2026 | americanbankingnews.comSpruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceNovember 2, 2026 | marketscreener.comMSpruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceNovember 2, 2026 | businesswire.comSee More Headlines SPRB Stock Analysis - Frequently Asked Questions How have SPRB shares performed this year? Spruce Biosciences' stock was trading at $87.11 on January 1st, 2026. Since then, SPRB shares have decreased by 47.0% and is now trading at $46.20. How were Spruce Biosciences' earnings last quarter? Spruce Biosciences, Inc. (NASDAQ:SPRB) released its quarterly earnings data on Monday, November, 9th. The company reported ($8.51) EPS for the quarter, missing the consensus estimate of ($5.68) by $2.83. When did Spruce Biosciences' stock split? Shares of Spruce Biosciences reverse split on the morning of Monday, August 4th 2025.The 1-75 reverse split was announced on Thursday, July 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 1st 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Spruce Biosciences IPO? Spruce Biosciences (SPRB) raised $90 million in an initial public offering on Friday, October 9th 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets acted as the underwriters for the IPO. How do I buy shares of Spruce Biosciences? Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Spruce Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spruce Biosciences investors own include Advanced Micro Devices (AMD), Biofrontera (BFRI), NVIDIA (NVDA), Palantir Technologies (PLTR), Riot Platforms (RIOT), AMC Entertainment (AMC) and Ford Motor (F). Company Calendar Last Earnings11/09/2026Today11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SPRB's financial health is in the Green zone, according to TradeSmith. SPRB has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SPRB CIK1683553 Webwww.sprucebiosciences.com Phone415-655-4168FaxN/AEmployees8Year Founded2016Price Target and Rating Average Price Target for Spruce Biosciences$158.33 High Price Target$283.00 Low Price Target$104.00 Potential Upside/Downside+242.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($33.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-118.22% Return on Assets-88.36% Debt Debt-to-Equity Ratio0.06 Current Ratio4.83 Quick Ratio9.23 Sales & Book Value Annual Sales$4.91 million Price / Sales27.00 Cash FlowN/A Price / Cash FlowN/A Book Value$23.07 per share Price / Book2.00Miscellaneous Outstanding Shares2,870,000Free Float2,750,000Market Cap$132.59 million OptionableOptionable Beta3.57 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:SPRB) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRB Stock Alerts